Behavioral activation for depression: A comprehensive systematic review and meta-analysis

Why clinicians should know about it

• Picked for Pediatrics and Child Health (top studies of the week, 26 July 2026): Ranked by evidence level and journal quartile
• Picked for Psychiatry and Mental Health (top studies of the week, 26 July 2026).

Abstract

INTRODUCTION: No recent comprehensive meta-analysis has integrated the results of randomized controlled trials of Behavioral activation (BA), one of the most important treatments of depression. METHODS: We used the data from our meta-analytic research domain of randomized controlled trials on the treatment of depression and selected all trials on BA in all age and target groups, settings and comparators. RESULTS: We included 105 trials (13,933 patients), including 40 with low risk of bias. The standardized mean difference (SMD) of BA for adult outpatients compared with control conditions was 0.67 (95% confidence interval [CI]: 0.54 to 0.80; k = 61) with high heterogeneity (I2 = 71%; 95% CI: 63% to 78%) and a broad 95% prediction interval (PI; -0.11 to 1.46). This remained significant in most sensitivity analyses, and at 12 months after randomization. We found no significant difference between BA and other therapies (k = 27; SMD = 0.04; 95% CI: -0.10 to 0.18). Self-guided BA was also effective (k = 15; SMD = 0.36; 95% CI: 0.20 to 0.51), as was BA in institutional settings (k = 10; SMD = 0.36; 95% CI: 0.17 to 0.55). Too few trials were available to estimate the effects of BA in children and adolescents (k = 4) and when compared to pharmacotherapy in adults (k = 4). CONCLUSION: BA is an efficacious treatment of depression in adults and its effect is significant up to 12 months after randomization. BA has smaller but significant effects in a self-guided format and in institutional settings.

Abstract as published, via PubMed.